Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. - Wikidata - awgldk - TriplyDB

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

http://www.wikidata.org/entity/Q33457195

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Monoclonal antibodies for the treatment of cancer Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.Antibody Therapies in Cancer.Next generation of antibody therapy for cancer.CD248 facilitates tumor growth via its cytoplasmic domain.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Peptide-based targeting of the platelet-derived growth factor receptor beta.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Targeting the PDGF signaling pathway in tumor treatment The interconnectedness of cancer cell signaling.The major G-quadruplex formed in the human platelet-derived growth factor receptor β promoter adopts a novel broken-strand structure in K+ solution.Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.The War on Cancer rages on.Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.Research and development of next generation of antibody-based therapeutics Emerging antibody combinations in oncology.The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.PDGF and the progression of renal disease.Tumor angiogenesis and vascular normalization: alternative therapeutic targets.Vasculogenic cytokines in wound healing.Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.Platelet-Derived Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration.PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer

P2860

Q24628746-898897B4-9F92-4D34-96DD-2F639A12E004 Q27025966-FEB5FA39-F2FB-421D-9B57-04C84FBB101C Q27026936-7C859A81-1BBF-4978-BBED-06F3E7C45AAC Q30250273-0B9F2280-16DC-473A-81F6-D1DB85165405 Q31104000-B1A0349B-AEB6-492A-AEEF-4CBCE44ECA3C Q33579636-CBEDE8BE-6267-4B89-8B4C-F0EFE91522C8 Q33891662-98AC144D-F01E-44C0-BBEB-200C864101C2 Q34111693-83417030-6861-4EF5-83A9-F7817A4DB46B Q34335171-D60540A8-CF38-4FAA-9F64-D96646B7DE7E Q34352802-039C04EF-4CF3-45BB-A2A0-B9468008574F Q34393461-1DED27B3-669B-4BB3-8468-E0F0FB57745C Q35669733-C793837A-12FC-4F6F-A13F-DC5D2E488159 Q36191141-FBA75CE7-4F56-429F-89AB-BA28977A60C1 Q36828050-D5EC8B9F-503B-4CEA-91CB-F2AAE4561026 Q36962682-1AFCD964-B3A7-4D0D-BBED-07925166DEC0 Q37478602-E8414570-4321-4188-B59D-BC12BEC87E6D Q37696048-FCAB9D83-683A-4843-8A8B-818C291606F4 Q37778732-3CF38CBB-54B6-445C-89BB-CA39456E6524 Q37893414-8EA79810-3C74-496D-B5B4-0D098E4D682A Q37964960-18690B54-EF20-4EAE-AF5F-A1B033AE04D7 Q38072598-E3C4D916-90BD-43F8-B7CA-2E0E09D9AE2A Q38185014-F2384FAA-7C6B-4FB4-99A8-7EB8224EA343 Q39403862-507A5002-68A3-4E09-8AD4-EC60F21FD8F0 Q42257428-ADB3497D-19A5-4A6E-8101-9CC2E60AFA75 Q42373333-695E5423-AC13-4CE3-B8C5-2BE267EB34A9 Q47756210-DA70A633-CF0A-45DB-B24C-417963A6B95E Q50876050-22C0D17A-D4D0-4EF2-90F4-CBAA1C7C3A2E Q58803894-DD46C456-50BE-4411-8E03-5155E1CF56AB Q59138133-A4FE5FA3-CD3F-4E06-ABEB-C58D2EE2D506

P2860

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

http://www.wikidata.org/entity/Q33457195

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@ast

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@en

type

label

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@ast

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@en

prefLabel

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@ast

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@en

P1433

Q33457195-2A7A7F5E-DBEA-448B-AFBC-AFAD47B8245A

P1476

Q33457195-825180EA-3324-4CC9-8B04-31BA49201D6F

P2093

Q33457195-21A9E8D3-9DCA-4DCD-B343-5710A859C0D8

Q33457195-2394DBB7-735B-4483-8833-2BD5AA6F8ECB

Q33457195-2876BE43-9E31-441D-899D-27579885D005

Q33457195-3A67FBB9-1B00-404C-B438-28DC3A801BA2

Q33457195-49ADDF7A-3A46-447D-B3F8-741DFFB374D7

Q33457195-57F1AB7B-6E66-43DF-8719-211A62C801DF

Q33457195-60E996BD-75BE-4A5A-8D2A-74DEEBAB02C4

Q33457195-6FCFB0B5-21A2-4F3A-B2A0-B3332B1591B6

Q33457195-7BF42015-DD4D-425D-B98D-50C40F88B370

Q33457195-819B9713-A48F-4637-A4D3-DB2862B16C97

P2860

Q33457195-01341E9C-16B0-4D79-BD2B-90330B73694F

Q33457195-03D317FC-1F2F-4766-B59E-B6FA4E410F8F

Q33457195-085C2157-78F1-45FD-B3DC-34BD5F3DFDB8

Q33457195-0AC0D3D5-44E6-4037-A852-025219AE4727

Q33457195-102653C2-B666-4414-9476-B599363BCF98

Q33457195-1E294836-0D36-4A18-A945-A4E2405EAFA7

Q33457195-298CEF70-C921-4AE2-9BE4-C3D9E7EC8932

Q33457195-3554305F-FA8D-4D5B-B72E-B21D34CBF988

Q33457195-401CB582-7047-4440-AE65-4A2CE72F87B4

Q33457195-403F54EA-9CD8-40B0-91AD-11089211C576

P304

Q33457195-58E85BFF-80AE-4505-A578-0B74FD4C3F04

P31

Q33457195-53026C90-F979-4C15-BE23-88E4337382E2

P356

Q33457195-A5B1AA49-F9A8-4C39-8F90-F5A4E2E6F180

P433

Q33457195-EFD6647E-8D56-41E7-8BA2-8F9D2AA076B2

P478

Q33457195-EE4FF24A-DC3B-4E3B-AF27-0E91531CA41A

P577

Q33457195-B585BD88-FB61-4FAE-BEAE-F9C1ABAACA7E

P5875

Q33457195-07495147-2881-4DF8-BC24-4B1191943FAC

P698

Q33457195-A031BA9A-ABEC-4779-A9D8-A007EAFCB5E5

P921

Q33457195-4CADED7C-E5F3-49E0-A52B-1E3B73782AC8

Q33457195-8572C5CD-2CE9-4269-A499-98928587EB6E

P932

Q33457195-2108F083-4754-48E6-9636-1DA4B6306862

P356

P1433

P1476

Development of a fully human a ...... ty of an anti-VEGFR2 antibody.

@en

P2093

Anna Rohoza-Asandi

http://www.w3.org/2001/XMLSchema#string

Anthony Kayas

http://www.w3.org/2001/XMLSchema#string

Chris Damoci

http://www.w3.org/2001/XMLSchema#string

Dale L Ludwig

http://www.w3.org/2001/XMLSchema#string

Dhanvanthri S Deevi

http://www.w3.org/2001/XMLSchema#string

Haifan Zhang

http://www.w3.org/2001/XMLSchema#string

Huiling Li

http://www.w3.org/2001/XMLSchema#string

James Tonra

http://www.w3.org/2001/XMLSchema#string

Juqun Shen

http://www.w3.org/2001/XMLSchema#string

Kris Persaud

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

The role of pericytes in blood-vessel formation and maintenance

Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

Role of angiogenesis in tumor growth and metastasis

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

High interstitial fluid pressure - an obstacle in cancer therapy

A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.

Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

P304

594-604

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.09278

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26255017

http://www.w3.org/2001/XMLSchema#string

P698

19484148

http://www.w3.org/2001/XMLSchema#string

P921

P932

2685448

http://www.w3.org/2001/XMLSchema#string